NanoString nCounter Human Organ Transplant Panel
NanoString Technologies has launched its nCounter Human Organ Transplant panel, a new gene expression panel for evaluating the immune response following organ transplantation. The firm said that it created the assay in collaboration with the Banff Foundation for Allograft Pathology. The panel covers 770 genes and is customizable. It is designed for use with the predominant transplant organs including kidney, heart, lung, and liver. Genes included on the panel are involved in 37 pathways that are components of the immune response, tissue injury, and mechanisms of action for immunosuppressive drugs. The panel also includes probes to detect common viral infections that can cause issues with transplants, including BK polyomavirus, cytomegalovirus, and Epstein-Barr virus.
Ambry Genetics +RNAinsight
Ambry Genetics has launched +RNAinsight, a combined DNA and RNA genetic test for hereditary cancer syndromes that is designed to return more certain results to patients by using RNA sequencing to definitively classify otherwise ambiguous genetic alterations. While the RNA aspect of the test does not include all known cancer risk genes, it does focus on a subset that includes BRCA1 and 2, TP53, PTEN, and PALB2, among others. Ambry said that the turnaround time for the combined test matches the company's DNA-only hereditary cancer panel.
ATCC Genome Portal
ATCC has launched its ATCC Genome Portal, a publicly available database of reference-quality genome sequences that are matched to authenticated ATCC biological materials. Integrating low-passaged materials, standardized next-generation sequencing, and a hybrid assembly approach, the tool produces complete reference-quality genomes by combining highly accurate short reads with ultra-long reads. ATCC said that it has launched the portal with an initial 250 genome sequences of widely used bacterial strains.
For more new products and services, please visit the New Products page on our website